|
| Tuesday, January 16, 2024 |
|
|
Eisai Furthers Oncology Research Across Multiple Cancers at ASCO GI and ASCO GU 2024 |
| Eisai Co., Ltd. announced today the presentation of oncology research at two upcoming medical meetings taking place in-person in San Francisco, California and virtually. more info >> |
|
| Thursday, January 11, 2024 |
|
|
Eisai: The Scientific Advisory Group (SAG) to Convene to Discuss the Marketing Authorization Application for lecanemab in the EU |
| Eisai Co., Ltd. announced today that the Scientific Advisory Group (SAG) will convene to discuss the marketing authorization application (MAA) of lecanemab (generic name, brand name: LEQEMBI), which is currently under review by the European Medicines Agency (EMA). more info >> |
|
| Wednesday, January 10, 2024 |
|
">
Eisai: "LEQEMBI" (Lecanemab) Approved for the Treatment of Alzheimer's Disease in China
|
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI" (generic name: lecanemab-irmb) has been approved in China as a treatment of mild cognitive impairment (MCI) due to Alzheimer's disease (AD) and mild AD dementia. ">more info >> |
|
| Friday, December 29, 2023 |
|
|
Development of Prediction Model for Brain Amyloid-Beta Accumulation Using Wristband Sensor |
| Oita University and Eisai Co., Ltd. (Eisai) hereby announce the development of the world's first machine learning model to predict amyloid beta (Abeta) accumulation in the brain using a wristband sensor. more info >> |
|
| Tuesday, December 19, 2023 |
|
|
Eisai Submits Marketing Authorization Application in Japan for Anticancer Agent Tasurgratinib for Biliary Tract Cancer with Fgfr2 Gene Fusion |
| Eisai Co., Ltd. announced today that it has submitted a marketing authorization application in Japan for its in-house discovered fibroblast growth factor (FGF) receptor (FGFR1, FGFR2, FGFR3) selective tyrosine kinase inhibitor tasurgratinib succinate (generic name, development code: E7090, ?tasurgratinib?) for biliary tract cancer with FGFR2 gene fusion. more info >> |
|
| Thursday, December 14, 2023 |
|
|
Eisai and Mizuho Sign Sustainability-Linked Loan Agreement |
| Eisai Co., Ltd. and Mizuho Bank, Ltd. announced today that the companies have signed a sustainability-linked syndicated loan agreement, which comes into effect today. more info >> |
|
|
"LEQEMBI Intravenous Infusion" (Lecanemab) for the Treatment of Alzheimer's Disease to be Launched in Japan on December 20 |
| Eisai Co., Ltd. and Biogen Inc. announced today that humanized anti- soluble aggregated amyloid-beta (Abeta) monoclonal antibody "LEQEMBI Intravenous Infusion" (200 mg, 500mg, lecanemab) will be launched in Japan on December 20, following its scheduled inclusion in the price listing on the Japan National Health Insurance (NHI) Drug Price List. more info >> |
|
| Monday, December 11, 2023 |
|
|
Eisai and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-001 Trial Evaluating LENVIMA (lenvatinib) Plus KEYTRUDA (pembrolizumab) as First-Line Treatment for Patients with Advanced or Recurrent Endometrial Carcinoma |
| Eisai and Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) today announced that the Phase 3 LEAP-001 trial evaluating LENVIMA, the orally available multiple receptor tyrosine kinase inhibitor discovered by Eisai. more info >> |
|
| Thursday, November 30, 2023 |
|
|
Eisai's Sales Subsidiary Collaborates with Ministry of Public Health (MOPH) in Thailand |
| Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketing Co., Ltd., (Eisai Thailand) has made an agreement to collaborate with the Department of Medical Services (DMS), Ministry of Public Health (MOPH) of Thailand to further enhance the access to treatments for dementia including Alzheimer's disease (AD) in Thailand. more info >> |
|
| Wednesday, November 22, 2023 |
|
|
Eisai to Present Latest Data on Perampanel at The 77th American Epilepsy Society (AES) Annual Meeting |
| Eisai Co., Ltd. announced today that the company will have a total of nine poster presentations, including the latest data on its in-house discovered and developed anti-epileptic agent (AED) perampanel (product name: Fycompa) at the 77th American Epilepsy Society Annual Meeting (AES 2023), to be held in Orland, Florida and virtually from December 1-5, 2023. more info >> |
|
|
|
